Serum sex hormone levels are related to breast cancer risk in postmenopausal women.
Serum sex hormone levels are related to breast cancer risk in postmenopausal women.
复制标题
DOI：
10.1289/ehp.97105s3583
复制
发表时间：
1997-04
影响因子：
10.4
通讯作者：
Schatzkin A
中科院分区：
文献类型：
--
作者：
Dorgan JF;Longcope C;Stephenson HE Jr;Falk RT;Miller R;Franz C;Kahle L;Campbell WS;Tangrea JA;Schatzkin A
我们进行了一项巢式病例对照研究，以前瞻性地评估血清雌激素和雄激素与绝经后妇女乳腺癌风险的关系。从1977年到1987年，3375名绝经后妇女没有癌症，也没有服用替代雌激素，捐献了血液给哥伦比亚，密苏里州的乳腺癌血清库。其中72人随后被诊断患有乳腺癌。对于每种情况，使用发病率密度匹配选择两个在年龄和采血日期和时间上匹配的对照。采血时受试者的中位年龄为62岁;从采血到诊断的时间范围为不到1年至9.5年，中位时间为2.9年。乳腺癌的风险与血清雌激素和雄激素水平呈正相关。与最低四分位数的女性相比，非性激素结合球蛋白（非SHBG）结合（生物可利用）雌二醇最高四分位数的女性相对风险为5.2（95%置信区间[CI] = 1.5-18.5），睾酮最高四分位数的女性相对风险为6.2（95% CI = 2.0-19.0）。我们的研究结果提供了相当大的支持假设，血清中雌激素和雄激素浓度与绝经后妇女乳腺癌的后续诊断。
We conducted a nested case-control study to prospectively evaluate the relationship of serum estrogens and androgens to risk of breast cancer in postmenopausal women. From 1977 to 1987, 3375 postmenopausal women free of cancer and not taking replacement estrogens donated blood to the Breast Cancer Serum Bank in Columbia, Missouri. Of these, 72 were subsequently diagnosed with breast cancer. For each case, two controls matched on age and date and time of day of blood collection were selected using incidence density matching. The median age of subjects at blood collection was 62 years; the time from blood collection to diagnosis ranged from less than 1 to 9.5 years with a median of 2.9 years. Risk of breast cancer was positively and significantly associated with serum levels of estrogens and androgens. Compared to women in the lowest quartile, those in the highest quartile for non-sex hormone-binding globulin (non-SHBG) bound (bioavailable) estradiol had a relative risk of 5.2 (95% confidence interval [CI] = 1.5-18.5) and those in the highest quartile for testosterone had a relative risk of 6.2 (95% CI = 2.0-19.0). Our results lend considerable support to the hypothesis that serum concentrations of estrogens and androgens are related to the subsequent diagnosis of breast cancer in postmenopausal women.